This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 Oct 2011

India's Natco Pharma Signs with Mabxience for mAb Drug Substances

Natco will source four monoclonal antibodies from the Mabxience and use them to manufacture finished dosages.

Indian drug maker Natco Pharma has inked a pact with Mabxience, a unit of Swiss-based Chemo Sa Lugano, to purchase four monoclonal antibodies(mAbs) drug substances from Chemo and use them to manufacture finished dosage pharmaceutical formulations.


Three of the four products - Trastuzumab, Bevacizumab, and Rituximab - belong to the oncology segment, while Etanercept is used to treat autoimmune diseases.


Under the agreement, Natco will manufacture the products, undertake local clinical trials, file registration of dossiers, apply for market authorisations, and commercialise them in India and other Asian countries.


Hyderabad-based Natco expects to complete the initiative in two or three years.


Related News